- Home
- URGN vs BMBL Comparison
URGN vs BMBL Comparison
Compare URGN & BMBL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | URGN | BMBL |
|---|---|---|
| Founded | 2004 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 545.0M |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | URGN | BMBL |
|---|---|---|
| Price | $21.96 | $3.43 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 13 |
| Target Price | ★ $28.50 | $5.08 |
| AVG Volume (30 Days) | 928.6K | ★ 2.8M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $96,516,000.00 | ★ $1,003,141,000.00 |
| Revenue This Year | $27.96 | N/A |
| Revenue Next Year | $123.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.00 | N/A |
| 52 Week Low | $3.42 | $3.18 |
| 52 Week High | $30.00 | $8.82 |
Technical Indicators
Market Signals| Indicator | URGN | BMBL |
|---|---|---|
| Relative Strength Index (RSI) | 42.19 | 33.14 |
| Support Level | $21.74 | $3.57 |
| Resistance Level | $30.00 | $3.90 |
| Average True Range (ATR) | 1.56 | 0.18 |
| MACD | -0.72 | 0.08 |
| Stochastic Oscillator | 3.15 | 14.55 |
Price Performance
Historical ComparisonAbout URGN UroGen Pharma Ltd.
UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.
About BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.